Blog

Blog

Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potent cytotoxic effects of chemotherapeutic agents. The development of ADCs traces back over a century and mirrors advancements in molecular biology and biotechnology, resulting in several approved drugs used in oncology today.

Oct 22, 2024
Read time: 6 mins

Immune checkpoints are regulatory pathways in the immune system that modulate immune responses and maintain self-tolerance. They are crucial for preventing autoimmune reactions but can be exploited by tumors to avoid immune destruction. These checkpoints act as "brakes" on the immune system, limiting the intensity and duration of immune responses to minimize damage to normal tissues.

Oct 21, 2024
Read time: 10 mins

Antibody-based diagnostics are tests that utilize antibodies to detect specific molecules that are indicative of a particular disease or condition. These diagnostic tools leverage the high specificity of antibodies, and the ability to produce large quantities of them. For example, monoclonal antibodies (mAbs) can be developed to recognize unique antigenic determinants on specific pathogens associated with a disease.

Oct 21, 2024
Read time: 6 mins

Biointron’s AbDrop platform revolutionizes antibody discovery by combining high-throughput screening with advanced microfluidic technology, enabling the identification of diverse and high-affinity antibodies. This process starts by isolating plasma B cells from immunized animals, encapsulating them in microdroplets to preserve natural heavy and light chain pairing, a critical factor for developing functional therapeutic antibodies.

Oct 20, 2024
Read time: 2 mins

Antibody-drug conjugates (ADCs) represent a promising approach in oncology due to their ability to deliver cytotoxic drugs selectively to cancer cells. By combining the tumor-targeting specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic agents, ADCs are engineered to improve therapeutic outcomes while minimizing damage to healthy tissue. However, their therapeutic efficacy is not only dependent on the specific antibody or drug payload but also on a critical parameter known as the drug–antibody ratio (DAR).

Oct 19, 2024
Read time: 7 mins

Antibody production technologies encompass various methods used to produce antibodies for therapeutic, diagnostic, and research purposes. The following are some of the primary technologies used in antibody production.

Oct 17, 2024
Read time: 1 min

Antibody pharmacokinetics (PK) is the study of how the body interacts with antibodies after administration, particularly with absorption, distribution, metabolism, and excretion. It is essential in the drug development process, as it allows us to assess the antibody’s therapeutic efficacy and intensity.

Oct 16, 2024
Read time: 6 mins

Several factors can affect an antibody’s stability, including protein structure and concentration, temperature, interfaces, light exposure, contaminants, and agitation. This is of particular importance when developing antibody therapeutics for their immunogenicity potential. The instabilities may be either chemical, physical, or a combination of both.

Oct 15, 2024
Read time: 6 mins

Immunoinformatics, also known as computational immunology, is the combination of computer science and experimental immunology. Due to technological advancements in immunology research, large quantities of data are now available from genome sequencing, scientific literature, and clinical records.

Oct 14, 2024
Read time: 6 mins

Antibody glycosylation is the covalent attachment of carbohydrate (glycan) molecules to the protein chains of antibodies. This is a common type of post-translational modification that occurs within the cell's endoplasmic reticulum and Golgi apparatus.

Oct 13, 2024
Read time: 7 mins

In vitro display technologies are a group of methods used to display diverse antibody libraries on the surface of solid supports or particles like phage, yeast, ribosomes, and bacteria. They are powerful tools for the discovery and engineering of novel antibodies with desired binding properties and were first explored for antibody selection over 30 years ago.

Oct 12, 2024
Read time: 7 mins

Chimeric antibodies, formed by combining the variable regions of one species with the constant domains of another, are essential for various research fields, especially in vivo and in vitro studies. These hybrid antibodies maintain their antigen-binding specificity while offering flexibility in different research settings. This flexibility makes them highly valuable for biotherapeutic research, immunoassays, and diagnostic applications.

Oct 11, 2024
Read time: 2 mins

Keep yourself updated with Biointron Insights

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.